Targeting the ubiquitin-proteasome system for cancer treatment: discovering novel inhibitors from nature and drug repurposing

1.

Ciechanover, A. (1994). The ubiquitin-proteasome proteolytic pathway. Cell, 79(1), 13–21.PubMedCrossRef

2.

Hochstrasser, M. (1995). Ubiquitin, proteasomes, and the regulation of intracellular protein degradation. Current Opinion in Cell Biology, 7(2), 215–223.PubMedCrossRef

3.

Goldberg, A. L., Akopian, T. N., Kisselev, A. F., Lee, D. H., & Rohrwild, M. (1997). New insights into the mechanisms and importance of the proteasome in intracellular protein degradation. Biological Chemistry, 378(3–4), 131–140.PubMed

4.

Dou, Q. P., & Zonder, J. A. (2014). Overview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system. Current Cancer Drug Targets, 14(6), 517–536.PubMedPubMedCentralCrossRef

5.

Mocciaro, A., & Rape, M. (2012). Emerging regulatory mechanisms in ubiquitin-dependent cell cycle control. Journal of Cell Science, 125(Pt 2), 255–263. https://doi.org/10.1242/jcs.091199.PubMedPubMedCentralCrossRef

6.

Orlowski, R. Z. (1999). The role of the ubiquitin-proteasome pathway in apoptosis. Cell Death & Differentiation, 6(4), 303.CrossRef

7.

Daulny, A., & Tansey, W. P. (2009). Damage control: DNA repair, transcription, and the ubiquitin–proteasome system. DNA Repair, 8(4), 444–448. https://doi.org/10.1016/j.dnarep.2009.01.017.PubMedCrossRef

8.

Strous, G. J., & Govers, R. (1999). The ubiquitin-proteasome system and endocytosis. Journal of Cell Science, 112(10), 1417.PubMed

9.

Ruckrich, T., Kraus, M., Gogel, J., Beck, A., Ovaa, H., Verdoes, M., et al. (2009). Characterization of the ubiquitin-proteasome system in bortezomib-adapted cells. Leukemia, 23(6), 1098–1105. https://doi.org/10.1038/leu.2009.8.PubMedCrossRef

10.

Rahimi, N. (2012). The ubiquitin-proteasome system meets angiogenesis. Molecular Cancer Therapeutics, 11(3), 538–548. https://doi.org/10.1158/1535-7163.mct-11-0555.PubMedPubMedCentralCrossRef

11.

Xie, P., Fan, Y., Zhang, H., Zhang, Y., She, M., Gu, D., et al. (2009). CHIP represses myocardin-induced smooth muscle cell differentiation via ubiquitin-mediated proteasomal degradation. Molecular and Cellular Biology, 29(9), 2398–2408. https://doi.org/10.1128/mcb.01737-08.PubMedPubMedCentralCrossRef

12.

Tu, Y., Chen, C., Pan, J., Xu, J., Zhou, Z.-G., & Wang, C.-Y. (2012). The ubiquitin proteasome pathway (UPP) in the regulation of cell cycle control and DNA damage repair and its implication in tumorigenesis. International Journal of Clinical and Experimental Pathology, 5(8), 726–738.PubMedPubMedCentral

13.

Milacic, V., Chen, D., Ronconi, L., Landis-Piwowar, K. R., Fregona, D., & Dou, Q. P. (2006). A novel anticancer gold(III) dithiocarbamate compound inhibits the activity of a purified 20S proteasome and 26S proteasome in human breast cancer cell cultures and xenografts. Cancer Research, 66(21), 10478–10486. https://doi.org/10.1158/0008-5472.can-06-3017.PubMedCrossRef

14.

Dalla Via, L., Nardon, C., & Fregona, D. (2012). Targeting the ubiquitin-proteasome pathway with inorganic compounds to fight cancer: a challenge for the future. Future Medicinal Chemistry, 4(4), 525–543. https://doi.org/10.4155/fmc.11.187.PubMedCrossRef

15.

Glickman, M. H., & Ciechanover, A. (2002). The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiological Reviews, 82(2), 373–428. https://doi.org/10.1152/physrev.00027.2001.PubMedCrossRef

16.

Hershko, A., & Ciechanover, A. (1998). The ubiquitin system. Annual Review of Biochemistry, 67, 425–479. https://doi.org/10.1146/annurev.biochem.67.1.425.PubMedCrossRef

17.

Chaugule, V. K., & Walden, H. (2016). Specificity and disease in the ubiquitin system. Biochemical Society Transactions, 44(1), 212–227. https://doi.org/10.1042/BST20150209.PubMedPubMedCentralCrossRef

18.

Lee, I., & Schindelin, H. (2008). Structural insights into E1-catalyzed ubiquitin activation and transfer to conjugating enzymes. Cell, 134(2), 268–278. https://doi.org/10.1016/j.cell.2008.05.046.PubMedCrossRef

19.

Sigismund, S., Polo, S., & Di Fiore, P. P. (2004). Signaling through Monoubiquitination. In I. H. Madshus (Ed.), Signalling from internalized growth factor receptors (pp. 149–185). Berlin: Springer Berlin Heidelberg.CrossRef

20.

Wood, A., Schneider, J., Dover, J., Johnston, M., & Shilatifard, A. (2003). The Paf1 complex is essential for histone monoubiquitination by the Rad6-Bre1 complex, which signals for histone methylation by COMPASS and Dot1p. Journal of Biological Chemistry, 278(37), 34739–34742. https://doi.org/10.1074/jbc.C300269200.PubMedCrossRef

21.

Braten, O., Livneh, I., Ziv, T., Admon, A., Kehat, I., Caspi, L. H., et al. (2016). Numerous proteins with unique characteristics are degraded by the 26S proteasome following monoubiquitination. Proceedings of the National Academy of Sciences, 113(32), E4639–E4647.CrossRef

22.

Sadowski, M., Suryadinata, R., Tan, A. R., Roesley, S. N. A., & Sarcevic, B. (2012). Protein monoubiquitination and polyubiquitination generate structural diversity to control distinct biological processes. IUBMB Life, 64(2), 136–142. https://doi.org/10.1002/iub.589.PubMedCrossRef

23.

Ristic, G., Tsou, W.-L., & Todi, S. V. (2014). An optimal ubiquitin-proteasome pathway in the nervous system: the role of deubiquitinating enzymes. Frontiers in Molecular Neuroscience, 7, 72. https://doi.org/10.3389/fnmol.2014.00072.PubMedPubMedCentralCrossRef

24.

Dambacher, C. M., Worden, E. J., Herzik, M. A., Martin, A., & Lander, G. C. (2016). Atomic structure of the 26S proteasome lid reveals the mechanism of deubiquitinase inhibition. eLife, 5, e13027. https://doi.org/10.7554/eLife.13027.PubMedPubMedCentralCrossRef

25.

Isono, E., & Nagel, M.-K. (2014). Deubiquitylating enzymes and their emerging role in plant biology. Frontiers in Plant Science, 5, 56. https://doi.org/10.3389/fpls.2014.00056.PubMedPubMedCentralCrossRef

26.

Chen, D., Frezza, M., Schmitt, S., Kanwar, J., & Dou, Q. P. (2011). Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives. Current Cancer Drug Targets, 11(3), 239–253.PubMedPubMedCentralCrossRef

27.

Andreas Schweitzer, A. A., Rudack, T., Beck, F., Pfeifer, G., Plitzko, J. M., Sakata, E., Schulten, K., Forster, F., & Baumeister, W. (2016). Structure of the human 26S proteasome at a resolution of 3.9 Å. Proceedings of the National Academy of Sciences of the United States. https://doi.org/10.1073/pnas.1608050113.

28.

Paraskevopoulos, K., Kriegenburg, F., Tatham, M. H., Rösner, H. I., Medina, B., Larsen, I. B., et al. (2014). Dss1 is a 26S proteasome ubiquitin receptor. Molecular Cell, 56(3), 453–461. https://doi.org/10.1016/j.molcel.2014.09.008.PubMedPubMedCentralCrossRef

29.

Weyburne, E. S., Wilkins, O. M., Sha, Z., Williams, D. A., Pletnev, A. A., de Bruin, G., et al. (2017). Inhibition of the proteasome β2 site sensitizes triple-negative breast cancer cells to β5 inhibitors and suppresses Nrf1 activation. Cell Chemical Biology, 24(2), 218–230. https://doi.org/10.1016/j.chembiol.2016.12.016.PubMedCrossRef

30.

Livneh, I., Cohen-Kaplan, V., Cohen-Rosenzweig, C., Avni, N., & Ciechanover, A. (2016). The life cycle of the 26S proteasome: from birth, through regulation and function, and onto its death. Cell Research, 26(8), 869–885. https://doi.org/10.1038/cr.2016.86.PubMedPubMedCentralCrossRef

31.

Ferrington, D. A., & Gregerson, D. S. (2012). Immunoproteasomes: structure, function, and antigen presentation. Progress in Molecular Biology and Translational Science, 109, 75–112. https://doi.org/10.1016/B978-0-12-397863-9.00003-1.PubMedPubMedCentralCrossRef

32.

Saeki, Y., Toh-e, A., Kudo, T., Kawamura, H., & Tanaka, K. (2009). Multiple proteasome-interacting proteins assist the assembly of the yeast 19S regulatory particle. Cell, 137(5), 900–913. https://doi.org/10.1016/j.cell.2009.05.005.PubMedCrossRef

33.

Tanaka, K. (2009). The proteasome: overview of structure and functions. Proceedings of the Japan Academy. Series B, Physical and Biological Sciences, 85(1), 12–36. https://doi.org/10.2183/pjab.85.12.PubMedPubMedCentralCrossRef

34.

D'Arcy, P., Wang, X., & Linder, S. (2015). Deubiquitinase inhibition as a cancer therapeutic strategy. Pharmacology & Therapeutics, 147, 32–54. https://doi.org/10.1016/j.pharmthera.2014.11.002.CrossRef

35.

Sridhar, S., Bhat, G., & Guruprasad, K. (2013). Analysis of bortezomib inhibitor docked within the catalytic subunits of the Plasmodium falciparum 20S proteasome. SpringerPlus, 2, 566. https://doi.org/10.1186/2193-1801-2-566.PubMedPubMedCentralCrossRef

36.

Adams, J., & Kauffman, M. (2004). Development of the proteasome inhibitor Velcade (bortezomib). Cancer Investigation, 22(2), 304–311.PubMedCrossRef

37.

Evan, G. I., & Vousden, K. H. (2001). Proliferation, cell cycle and apoptosis in cancer. Nature, 411(6835), 342–348. https://doi.org/10.1038/35077213.PubMedCrossRef

38.

Chen, L., & Madura, K. (2005). Increased proteasome activity, ubiquitin-conjugating enzymes, and eEF1A translation factor detected in breast cancer tissue. Cancer Research, 65(13), 5599. https://doi.org/10.1158/0008-5472.CAN-05-0201.PubMedCrossRef

39.

Kumatori, A., Tanaka, K., Inamura, N., Sone, S., Ogura, T., Matsumoto, T., et al. (1990). Abnormally high expression of proteasomes in human leukemic cells. Proceedings of the National Academy of Sciences of the United States of America, 87(18), 7071–7075.PubMedPubMedCentralCrossRef

40.

Arlt, A., Bauer, I., Schafmayer, C., Tepel, J., Muerkoster, S. S., Brosch, M., et al. (2009). Increased proteasome subunit protein expression and proteasome activity in colon cancer relate to an enhanced activation of nuclear factor E2-related factor 2 (Nrf2). Oncogene, 28(45), 3983–3996. https://doi.org/10.1038/onc.2009.264.PubMedCrossRef

41.

Adams, J. (2003). The proteasome: structure, function, and role in the cell. Cancer Treatment Reviews, 29, 3–9. https://doi.org/10.1016/S0305-7372(03)00081-1.PubMedCrossRef

42.

Delic, J., Masdehors, P., Omura, S., Cosset, J. M., Dumont, J., Binet, J. L., et al. (1998). The proteasome inhibitor lactacystin induces apoptosis and sensitizes chemo- and radioresistant human chronic lymphocytic leukaemia lymphocytes to TNF-alpha-initiated apoptosis. British Journal of Cancer, 77(7), 1103–1107.PubMedPubMedCentralCrossRef

43.

LeBlanc, R., Catley, L. P., Hideshima, T., Lentzsch, S., Mitsiades, C. S., Mitsiades, N., et al. (2002). Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Research, 62(17), 4996–5000.PubMed

44.

An, B., Goldfarb, R. H., Siman, R., & Dou, Q. P. (1998 Dec). Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts. Cell Death and Differentiation, 5(12), 1062–7545.PubMedCrossRef

45.

Lipchick, B. C., Fink, E. E., & Nikiforov, M. A. (2016). Oxidative stress and proteasome inhibitors in multiple myeloma. Pharmacological Research, 105, 210–215. https://doi.org/10.1016/j.phrs.2016.01.029.PubMedPubMedCentralCrossRef

46.

Wang, X., Yen, J., Kaiser, P., & Huang, L. (2010). Regulation of the 26S proteasome complex during oxidative stress. Science Signaling, 3(151), ra88. https://doi.org/10.1126/scisignal.2001232.PubMedPubMedCentralCrossRef

47.

Aiken, C. T., Kaake, R. M., Wang, X., & Huang, L. (2011). Oxidative stress-mediated regulation of proteasome complexes. Molecular & Cellular Proteomics : MCP, 10(5), R110.006924. https://doi.org/10.1074/mcp.M110.006924.PubMedPubMedCentralCrossRef

48.

Crawford, L. J. A., Walker, B., Ovaa, H., Chauhan, D., Anderson, K. C., Morris, T. C. M., et al. (2006). Comparative selectivity and specificity of the proteasome inhibitors BzLLLCOCHO, PS-341, and MG-132. Cancer Research, 66(12), 6379. https://doi.org/10.1158/0008-5472.CAN-06-0605.PubMedCrossRef

49.

Kazi, A., Lawrence, H., Guida, W. C., McLaughlin, M. L., Springett, G. M., Berndt, N., et al. (2009). Discovery of a novel proteasome inhibitor selective for cancer cells over non-transformed cells. Cell Cycle, 8(12), 1940–1951. https://doi.org/10.4161/cc.8.12.8798.PubMedPubMedCentralCrossRef

50.

Ding, W.-X., Ni, H.-M., Gao, W., Chen, X., Kang, J. H., Stolz, D. B., et al. (2009). Oncogenic transformation confers a selective susceptibility to the combined suppression of the proteasome and autophagy. Molecular Cancer Therapeutics, 8(7), 2036–2045. https://doi.org/10.1158/1535-7163.MCT-08-1169.PubMedPubMedCentralCrossRef

51.

Zhou, Y., Wang, K., Zhen, S., Wang, R., & Luo, W. (2016). Carfilzomib induces G2/M cell cycle arrest in human endometrial cancer cells via upregulation of p21Waf1/Cip1 and p27Kip1. Taiwanese Journal of Obstetrics & Gynecology, 55(6), 847–851. https://doi.org/10.1016/j.tjog.2016.09.003.CrossRef

52.

Huang, H., Liu, N., Liao, Y., Liu, N., Cai, J., Xia, X., et al. (2017). Platinum-containing compound platinum pyrithione suppresses ovarian tumor proliferation through proteasome inhibition. Journal of Experimental & Clinical Cancer Research : CR, 36, 79. https://doi.org/10.1186/s13046-017-0547-8.PubMedCentralCrossRef

53.

Drexler, H. C. A. (1997). Activation of the cell death program by inhibition of proteasome function. Proceedings of the National Academy of Sciences of the United States of America, 94(3), 855–860.PubMedPubMedCentralCrossRef

54.

Pandit, B., & Gartel, A. L. (2011). Proteasome inhibitors induce p53-independent apoptosis in human cancer cells. The American Journal of Pathology, 178(1), 355–360. https://doi.org/10.1016/j.ajpath.2010.11.010.PubMedPubMedCentralCrossRef

55.

Nam, S., Smith, D. M., & Dou, Q. P. (2001). Tannic acid potently inhibits tumor cell proteasome activity, increases p27 and Bax expression, and induces G<sub>1</sub> arrest and apoptosis. Cancer Epidemiology Biomarkers &amp; Prevention, 10(10), 1083.

56.

Mortenson, M. M., Schlieman, M. G., Virudachalam, S., Lara, P. N., Gandara, D. G., Davies, A. M., et al. (2005). Reduction in BCL-2 levels by 26S proteasome inhibition with bortezomib is associated with induction of apoptosis in small cell lung cancer. Lung Cancer, 49(2), 163–170. https://doi.org/10.1016/j.lungcan.2005.01.006.PubMedCrossRef

57.

Adams, J. (2003). Potential for proteasome inhibition in the treatment of cancer. Drug Discovery Today, 8(7), 307–315.PubMedCrossRef

58.

Liu, Y., Huang, X., He, X., Zhou, Y., Jiang, X., Chen-Kiang, S., et al. (2015). A novel effect of thalidomide and its analogs: suppression of cereblon ubiquitination enhances ubiquitin ligase function. The FASEB Journal, 29(12), 4829–4839. https://doi.org/10.1096/fj.15-274050.PubMedPubMedCentralCrossRef

59.

Lopez-Girona, A., Mendy, D., Ito, T., Miller, K., Gandhi, A. K., Kang, J., et al. (2012). Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia, 26(11), 2326–2335. https://doi.org/10.1038/leu.2012.119.PubMedPubMedCentralCrossRef

60.

Kubiczkova, L., Pour, L., Sedlarikova, L., Hajek, R., & Sevcikova, S. (2014). Proteasome inhibitors—molecular basis and current perspectives in multiple myeloma. Journal of Cellular and Molecular Medicine, 18(6), 947–961. https://doi.org/10.1111/jcmm.12279.PubMedPubMedCentralCrossRef

61.

Buac, D., Shen, M., Schmitt, S., Kona, F. R., Deshmukh, R., Zhang, Z., et al. (2013). From bortezomib to other inhibitors of the proteasome and beyond. Current Pharmaceutical Design, 19(22), 4025–4038.PubMedPubMedCentralCrossRef

62.

Moreau, P., Pylypenko, H., Grosicki, S., Karamanesht, I., Leleu, X., Grishunina, M., et al. (2011). Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. The Lancet Oncology, 12(5), 431–440. https://doi.org/10.1016/S1470-2045(11)70081-X.PubMedCrossRef

63.

Lü, S., & Wang, J. (2013). The resistance mechanisms of proteasome inhibitor bortezomib. Biomarker Research, 1, 13–13. https://doi.org/10.1186/2050-7771-1-13.PubMedPubMedCentralCrossRef

64.

Steiner, R. E., & Manasanch, E. E. (2017). Carfilzomib boosted combination therapy for relapsed multiple myeloma. Onco Targets Ther, 10, 895–907. https://doi.org/10.2147/ott.s102756.PubMedPubMedCentralCrossRef

65.

Sonneveld, P., & Broijl, A. (2016). Treatment of relapsed and refractory multiple myeloma. Haematologica, 101(4), 396–406. https://doi.org/10.3324/haematol.2015.129189.PubMedPubMedCentralCrossRef

66.

Riz, I., Hawley, T. S., & Hawley, R. G. (2015). KLF4-SQSTM1/p62-associated prosurvival autophagy contributes to carfilzomib resistance in multiple myeloma models. Oncotarget, 6(17), 14814–14831. https://doi.org/10.18632/oncotarget.4530.PubMedPubMedCentralCrossRef

67.

Yang, C. S., & Landau, J. M. (2000). Effects of tea consumption on nutrition and health. The Journal of Nutrition, 130(10), 2409–2412.PubMed

68.

Nam, S., Smith, D. M., & Dou, Q. P. (2001). Ester bond-containing tea polyphenols potently inhibit proteasome activity in vitro and in vivo. The Journal of Biological Chemistry, 276(16), 13322–13330. https://doi.org/10.1074/jbc.M004209200.PubMedCrossRef

69.

Lachman, H. M., Papolos, D. F., Saito, T., Yu, Y. M., Szumlanski, C. L., & Weinshilboum, R. M. (1996). Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics, 6(3), 243–250.PubMedCrossRef

70.

Weinshilboum, R. M., Otterness, D. M., & Szumlanski, C. L. (1999). Methylation pharmacogenetics: catechol O-methyltransferase, thiopurine methyltransferase, and histamine N-methyltransferase. Annual Review of Pharmacology and Toxicology, 39, 19–52. https://doi.org/10.1146/annurev.pharmtox.39.1.19.PubMedCrossRef

71.

Landis-Piwowar, K., Chen, D., Chan, T. H., & Dou, Q. P. (2010). Inhibition of catechol-O-methyltransferase activity in human breast cancer cells enhances the biological effect of the green tea polyphenol (−)-EGCG. Oncology Reports, 24(2), 563–569.PubMedPubMedCentral

72.

Huo, C., Yang, H., Cindy Cui, Q., Dou, Q. P., & Chan, T. H. (2010). Proteasome inhibition in human breast cancer cells with high catechol-O-methyltransferase activity by green tea polyphenol EGCG analogs. Bioorganic & Medicinal Chemistry, 18(3), 1252. https://doi.org/10.1016/j.bmc.2009.12.034.CrossRef

73.

Kanwar, J., Mohammad, I., Yang, H., Huo, C., Chan, T. H., & Dou, Q. P. (2010). Computational modeling of the potential interactions of the proteasome β5 subunit and catechol-O-methyltransferase-resistant EGCG analogs. International Journal of Molecular Medicine, 26(2), 209–215.PubMedPubMedCentral

74.

Barrett, J. R. (2006). The science of soy: what do we really know? Environmental Health Perspectives, 114(6), A352–A358.PubMedPubMedCentralCrossRef

75.

Kazi, A., Daniel, K. G., Smith, D. M., Kumar, N. B., & Dou, Q. P. (2003). Inhibition of the proteasome activity, a novel mechanism associated with the tumor cell apoptosis-inducing ability of genistein. Biochemical Pharmacology, 66(6), 965–976.PubMedCrossRef

76.

Shim, S. H. (2011). 20S proteasome inhibitory activity of flavonoids isolated from Spatholobus suberectus. Phytotherapy Research, 25(4), 615–618. https://doi.org/10.1002/ptr.3342.PubMedCrossRef

77.

Egert, S., & Rimbach, G. (2011). Which sources of flavonoids: Complex diets or dietary supplements? Advances in Nutrition, 2(1), 8–14. https://doi.org/10.3945/an.110.000026.PubMedPubMedCentralCrossRef

78.

Chen, D., Daniel, K. G., Chen, M. S., Kuhn, D. J., Landis-Piwowar, K. R., & Dou, Q. P. (2005). Dietary flavonoids as proteasome inhibitors and apoptosis inducers in human leukemia cells. Biochemical Pharmacology, 69(10), 1421–1432. https://doi.org/10.1016/j.bcp.2005.02.022.PubMedCrossRef

79.

Srivastava, J. K., Shankar, E., & Gupta, S. (2010). Chamomile: a herbal medicine of the past with bright future. Molecular Medicine Reports, 3(6), 895–901. https://doi.org/10.3892/mmr.2010.377.PubMedPubMedCentral

80.

Chen, D., Landis-Piwowar, K. R., Chen, M. S., & Dou, Q. P. (2007). Inhibition of proteasome activity by the dietary flavonoid apigenin is associated with growth inhibition in cultured breast cancer cells and xenografts. Breast Cancer Research, 9(6), R80.PubMedPubMedCentralCrossRef

81.

Yuan, R., & Lin, Y. (2000). Traditional Chinese medicine. Pharmacology & Therapeutics, 86(2), 191–198. https://doi.org/10.1016/S0163-7258(00)00039-5.CrossRef

82.

Ergil, K. V., Kramer, E. J., & Ng, A. T. (2002). Chinese herbal medicines. Western Journal of Medicine, 176(4), 275–279.PubMedPubMedCentral

83.

Dai, Y., DeSano, J., Tang, W., Meng, X., Meng, Y., Burstein, E., et al. (2010). Natural proteasome inhibitor celastrol suppresses androgen-independent prostate cancer progression by modulating apoptotic proteins and NF-kappaB. PLoS One, 5(12), e14153. https://doi.org/10.1371/journal.pone.0014153.PubMedPubMedCentralCrossRef

84.

Pang, X., Yi, Z., Zhang, J., Lu, B., Sung, B., Qu, W., et al. (2010). Celastrol suppresses angiogenesis-mediated tumor growth through inhibition of AKT/mammalian target of rapamycin pathway. Cancer Research, 70(5), 1951–1959. https://doi.org/10.1158/0008-5472.CAN-09-3201.PubMedPubMedCentralCrossRef

85.

Raja, S. M., Clubb, R. J., Ortega-Cava, C., Williams, S. H., Bailey, T. A., Duan, L., et al. (2011). Anticancer activity of celastrol in combination with ErbB2-targeted therapeutics for treatment of ErbB2-overexpressing breast cancers. Cancer Biology & Therapy, 11(2), 263–276. https://doi.org/10.4161/cbt.11.2.13959.CrossRef

86.

Yang, H., Chen, D., Cui, Q. C., Yuan, X., & Dou, Q. P. (2006). Celastrol, a triterpene extracted from the Chinese “Thunder of God Vine,” is a potent proteasome inhibitor and suppresses human prostate cancer growth in nude mice. Cancer Research, 66(9), 4758–4765. https://doi.org/10.1158/0008-5472.can-05-4529.PubMedCrossRef

87.

Mahajan, K., Malla, P., Lawrence, H. R., Chen, Z., Kumar-Sinha, C., Malik, R., et al. (2017). ACK1/TNK2 regulates histone H4 Tyr88-phosphorylation and AR gene expression in castration-resistant prostate cancer. Cancer Cell, 31(6), 790–803.e798. https://doi.org/10.1016/j.ccell.2017.05.003.PubMedCrossRef

88.

Chen, M., Rose, A. E., Doudican, N., Osman, I., & Orlow, S. J. (2009). Celastrol synergistically enhances temozolomide cytotoxicity in melanoma cells. Molecular Cancer Research, 7(12), 1946–1953. https://doi.org/10.1158/1541-7786.mcr-09-0243.PubMedCrossRef

89.

Yang, H., Landis-Piwowar, K. R., Lu, D., Yuan, P., Li, L., Reddy, G. P., et al. (2008). Pristimerin induces apoptosis by targeting the proteasome in prostate cancer cells. Journal of Cellular Biochemistry, 103(1), 234–244. https://doi.org/10.1002/jcb.21399.PubMedCrossRef

90.

Lu, L., Kanwar, J., Schmitt, S., Cui, Q. C., Zhang, C., Zhao, C., et al. (2011). Inhibition of tumor cellular proteasome activity by triptolide extracted from the Chinese medicinal plant 'thunder god vine'. Anticancer Research, 31(1), 1–10.PubMedPubMedCentral

91.

Yang, H., Zhou, P., Huang, H., Chen, D., Ma, N., Cui, Q. C., et al. (2009). Shikonin exerts antitumor activity via proteasome inhibition and cell death induction in vitro and in vivo. International Journal of Cancer, 124(10), 2450–2459. https://doi.org/10.1002/ijc.24195.PubMedPubMedCentralCrossRef

92.

Mirjalili, M. H., Moyano, E., Bonfill, M., Cusido, R. M., & Palazon, J. (2009). Steroidal lactones from Withania somnifera, an ancient plant for novel medicine. Molecules, 14(7), 2373–2393. https://doi.org/10.3390/molecules14072373.PubMedCrossRef

93.

Yang, H., Shi, G., & Dou, Q. P. (2007). The tumor proteasome is a primary target for the natural anticancer compound Withaferin A isolated from “Indian winter cherry”. Molecular Pharmacology, 71(2), 426–437. https://doi.org/10.1124/mol.106.030015.PubMedCrossRef

94.

Hatcher, H., Planalp, R., Cho, J., Torti, F. M., & Torti, S. V. (2008). Curcumin: From ancient medicine to current clinical trials. Cellular and molecular life sciences : CMLS, 65(11), 1631–1652. https://doi.org/10.1007/s00018-008-7452-4.PubMedPubMedCentralCrossRef

95.

Milacic, V., Banerjee, S., Landis-Piwowar, K. R., Sarkar, F. H., Majumdar, A. P. N., & Dou, Q. P. (2008). Curcumin inhibits the proteasome activity in human colon cancer cells in vitro and in vivo. Cancer Research, 68(18), 7283–7292. https://doi.org/10.1158/0008-5472.CAN-07-6246.PubMedPubMedCentralCrossRef

96.

Wan, S. B., Yang, H., Zhou, Z., Cui, Q. C., Chen, D., Kanwar, J., et al. (2010). Evaluation of curcumin acetates and amino acid conjugates as proteasome inhibitors. International Journal of Molecular Medicine, 26(4), 447–455.PubMedPubMedCentral

97.

Yue, X., Zuo, Y., Ke, H., Luo, J., Lou, L., Qin, W., et al. (2017). Identification of 4-arylidene curcumin analogues as novel proteasome inhibitors for potential anticancer agents targeting 19S regulatory particle associated deubiquitinase. Biochemical Pharmacology, 137, 29–50. https://doi.org/10.1016/j.bcp.2017.04.032.PubMedCrossRef

98.

Henkel, T., Machleidt, T., Alkalay, I., Kronke, M., Ben-Neriah, Y., & Baeuerle, P. A. (1993). Rapid proteolysis of I[kappa]B-[alpha] is necessary for activation of transcription factor NF-[kappa]B. Nature, 365(6442), 182–185. https://doi.org/10.1038/365182a0.PubMedCrossRef

99.

Kashyap, D., Mondal, R., Tuli, H. S., Kumar, G., & Sharma, A. K. (2016). Molecular targets of gambogic acid in cancer: recent trends and advancements. Tumor Biology, 37(10), 12915–12925. https://doi.org/10.1007/s13277-016-5194-8.

100.

Zhou, Z. T., & W. J. (2007). Phase I human tolerability trial of gambogic acid. Chin J New Drugs, 16(1), 679–682.

101.

Li, X., Liu, S., Huang, H., Liu, N., Zhao, C., Liao, S., et al. (2013). Gambogic acid is a tissue-specific proteasome inhibitor in vitro and in vivo. Cell Reports, 3(1), 211–222. https://doi.org/10.1016/j.celrep.2012.11.023.PubMedCrossRef

102.

Shi, X., Chen, X., Li, X., Lan, X., Zhao, C., Liu, S., et al. (2014). Gambogic acid induces apoptosis in imatinib-resistant chronic myeloid leukemia cells via inducing proteasome inhibition and caspase-dependent Bcr-Abl downregulation. Clinical Cancer Research, 20(1), 151–163. https://doi.org/10.1158/1078-0432.ccr-13-1063.PubMedCrossRef

103.

Shi, X., Lan, X., Chen, X., Zhao, C., Li, X., Liu, S., et al. (2015). Gambogic acid induces apoptosis in diffuse large B-cell lymphoma cells via inducing proteasome inhibition. Scientific Reports, 5, 9694. https://doi.org/10.1038/srep09694.PubMedPubMedCentralCrossRef

104.

Barry, N. P. E., & Sadler, P. J. (2013). Exploration of the medical periodic table: towards new targets. Chemical Communications, 49(45), 5106–5131. https://doi.org/10.1039/C3CC41143E.PubMedCrossRef

105.

Dilruba, S., & Kalayda, G. V. (2016). Platinum-based drugs: past, present and future. Cancer Chemotherapy and Pharmacology, 77(6), 1103–1124. https://doi.org/10.1007/s00280-016-2976-z.PubMedCrossRef

106.

Tiekink, E. R. T. (2008). Anti-cancer potential of gold complexes. Inflammopharmacology, 16(3), 138–142. https://doi.org/10.1007/s10787-007-0018-5.PubMedCrossRef

107.

Nardon, C., Schmitt, S. M., Yang, H., Zuo, J., Fregona, D., & Dou, Q. P. (2014). Gold(III)-dithiocarbamato Peptidomimetics in the forefront of the targeted anticancer therapy: preclinical studies against human breast neoplasia. PLoS One, 9(1), e84248. https://doi.org/10.1371/journal.pone.0084248.PubMedPubMedCentralCrossRef

108.

Fiskus, W., Saba, N., Shen, M., Ghias, M., Liu, J., Gupta, S. D., et al. (2014). Auranofin induces lethal oxidative and endoplasmic reticulum stress and exerts potent preclinical activity against chronic lymphocytic leukemia. Cancer Research, 74(9), 2520–2532. https://doi.org/10.1158/0008-5472.can-13-2033.PubMedPubMedCentralCrossRef

109.

Phase I and II study of auranofin in chronic lymphocytic leukemia (CLL). https://clinicaltrials.gov/ct2/show/NCT01419691

110.

Madeira, J. M., Gibson, D. L., Kean, W. F., & Klegeris, A. (2012). The biological activity of auranofin: implications for novel treatment of diseases. Inflammopharmacology, 20(6), 297–306. https://doi.org/10.1007/s10787-012-0149-1.PubMedCrossRef

111.

Liu, N., Li, X., Huang, H., Zhao, C., Liao, S., Yang, C., et al. (2014). Clinically used antirheumatic agent auranofin is a proteasomal deubiquitinase inhibitor and inhibits tumor growth. Oncotarget, 5(14), 5453–5471. 10.18632/oncotarget.2113.PubMedPubMedCentralCrossRef

112.

Chen, X., Shi, X., Zhao, C., Li, X., Lan, X., Liu, S., et al. (2014). Anti-rheumatic agent auranofin induced apoptosis in chronic myeloid leukemia cells resistant to imatinib through both Bcr/Abl-dependent and -independent mechanisms. Oncotarget, 5(19), 9118–9132. 10.18632/oncotarget.2361.PubMedPubMedCentralCrossRef

113.

Varela-Ramirez, A., Costanzo, M., Carrasco, Y. P., Pannell, K. H., & Aguilera, R. J. (2011). Cytotoxic effects of two organotin compounds and their mode of inflicting cell death on four mammalian cancer cells. Cell Biology and Toxicology, 27(3), 159–168. https://doi.org/10.1007/s10565-010-9178-y.PubMedCrossRef

114.

Pellerito, L., & Nagy, L. (2002). Organotin(IV)n+ complexes formed with biologically active ligands: equilibrium and structural studies, and some biological aspects. Coordination Chemistry Reviews, 224(1), 111–150. https://doi.org/10.1016/S0010-8545(01)00399-X.CrossRef

115.

Nath, M., Yadav, R., Eng, G., & Musingarimi, P. (1999). Characteristic spectral studies and in vitro antimicrobial and in vivo multi-infection antifungal activities in mice of new organotin(IV) derivatives of heterocyclic amino acids. Applied Organometallic Chemistry, 13(1), 29–37. https://doi.org/10.1002/(SICI)1099-0739(199901)13:1<29::AID-AOC809>3.0.CO;2-D.CrossRef

116.

Shi, G., Chen, D., Zhai, G., Chen, M. S., Cui, Q. C., Zhou, Q., et al. (2009). The proteasome is a molecular target of environmental toxic organotins. Environmental Health Perspectives, 117(3), 379–386. https://doi.org/10.1289/ehp.11865.PubMedCrossRef

117.

Gupte, A., & Mumper, R. J. (2009). Elevated copper and oxidative stress in cancer cells as a target for cancer treatment. Cancer Treatment Reviews, 35(1), 32–46. https://doi.org/10.1016/j.ctrv.2008.07.004.PubMedCrossRef

118.

Kuo, H. W., Chen, S. F., Wu, C. C., Chen, D. R., & Lee, J. H. (2002). Serum and tissue trace elements in patients with breast cancer in Taiwan. Biological Trace Element Research, 89(1), 1–11. https://doi.org/10.1385/bter:89:1:1.PubMedCrossRef

119.

Zuo, X. L., Chen, J. M., Zhou, X., Li, X. Z., & Mei, G. Y. (2006). Levels of selenium, zinc, copper, and antioxidant enzyme activity in patients with leukemia. Biological Trace Element Research, 114(1–3), 41–53. https://doi.org/10.1385/bter:114:1:41.PubMedCrossRef

120.

Brem, S. S., Zagzag, D., Tsanaclis, A. M., Gately, S., Elkouby, M. P., & Brien, S. E. (1990). Inhibition of angiogenesis and tumor growth in the brain. Suppression of endothelial cell turnover by penicillamine and the depletion of copper, an angiogenic cofactor. The American Journal of Pathology, 137(5), 1121–1142.PubMedPubMedCentral

121.

Daniel, K. G., Gupta, P., Harbach, R. H., Guida, W. C., & Dou, Q. P. (2004). Organic copper complexes as a new class of proteasome inhibitors and apoptosis inducers in human cancer cells. Biochemical Pharmacology, 67(6), 1139–1151. https://doi.org/10.1016/j.bcp.2003.10.031.PubMedCrossRef

122.

Liu, N., Liu, C., Li, X., Liao, S., Song, W., Yang, C., et al. (2014). A novel proteasome inhibitor suppresses tumor growth via targeting both 19S proteasome deubiquitinases and 20S proteolytic peptidases. Scientific Reports, 4, 5240. https://doi.org/10.1038/srep05240.PubMedPubMedCentralCrossRef

123.

Hindo, S. S., Frezza, M., Tomco, D., Heeg, M. J., Hryhorczuk, L., McGarvey, B. R., et al. (2009). Metals in anticancer therapy: copper(II) complexes as inhibitors of the 20S proteasome. European Journal of Medicinal Chemistry, 44(11), 4353–4361. https://doi.org/10.1016/j.ejmech.2009.05.019.PubMedPubMedCentralCrossRef

124.

Frezza, M., Hindo, S. S., Tomco, D., Allard, M., Cui, Q. C., Heeg, M. J., et al. (2009). Comparative activities of nickel(II) and zinc(II) complexes of asymmetric [NN′O] ligands as 26S proteasome inhibitors. Inorganic Chemistry, 48(13), 5928–5937. https://doi.org/10.1021/ic900276g.PubMedPubMedCentralCrossRef

125.

Verani, C. N. (2012). Metal complexes as inhibitors of the 26S proteasome in tumor cells. Journal of Inorganic Biochemistry, 106(1), 59–67. https://doi.org/10.1016/j.jinorgbio.2011.09.003.PubMedCrossRef

126.

Zhang, Z., Bi, C., Buac, D., Fan, Y., Zhang, X., Zuo, J., et al. (2013). Organic cadmium complexes as proteasome inhibitors and apoptosis inducers in human breast cancer cells. Journal of Inorganic Biochemistry, 0, 1–10. https://doi.org/10.1016/j.jinorgbio.2013.02.004.PubMedCentralCrossRef

127.

Kelland, L. (2007). The resurgence of platinum-based cancer chemotherapy. Nature Reviews. Cancer, 7(8), 573–584. https://doi.org/10.1038/nrc2167.PubMedCrossRef

128.

Rizk, S. L., & Sky-Peck, H. H. (1984). Comparison between concentrations of trace elements in normal and neoplastic human breast tissue. Cancer Research, 44(11), 5390–5394.PubMed

129.

Huang, Y. L., Sheu, J. Y., & Lin, T. H. (1999). Association between oxidative stress and changes of trace elements in patients with breast cancer. Clinical Biochemistry, 32(2), 131–136.PubMedCrossRef

130.

Habib, F. K., Dembinski, T. C., & Stitch, S. R. (1980). The zinc and copper content of blood leucocytes and plasma from patients with benign and malignant prostates. Clinica Chimica Acta, 104(3), 329–335.CrossRef

131.

Nayak, S. B., Bhat, V. R., Upadhyay, D., & Udupa, S. L. (2003). Copper and ceruloplasmin status in serum of prostate and colon cancer patients. Indian Journal of Physiology and Pharmacology, 47(1), 108–110.PubMed

132.

Diez, M., Arroyo, M., Cerdan, F. J., Munoz, M., Martin, M. A., & Balibrea, J. L. (1989). Serum and tissue trace metal levels in lung cancer. Oncology, 46(4), 230–234.PubMedCrossRef

133.

Turecky, L., Kalina, P., Uhlikova, E., Namerova, S., & Krizko, J. (1984). Serum ceruloplasmin and copper levels in patients with primary brain tumors. Klinische Wochenschrift, 62(4), 187–189.PubMedCrossRef

134.

Daniel, K. G., Chen, D., Orlu, S., Cui, Q. C., Miller, F. R., & Dou, Q. P. (2005). Clioquinol and pyrrolidine dithiocarbamate complex with copper to form proteasome inhibitors and apoptosis inducers in human breast cancer cells. Breast Cancer Research, 7(6), R897–R908. https://doi.org/10.1186/bcr1322.PubMedPubMedCentralCrossRef

135.

Zhai, S., Yang, L., Cui, Q. C., Sun, Y., Dou, Q. P., & Yan, B. (2010). Tumor cellular proteasome inhibition and growth suppression by 8-hydroxyquinoline and clioquinol requires their capabilities to bind copper and transport copper into cells. Journal of Biological Inorganic Chemistry, 15(2), 259–269. https://doi.org/10.1007/s00775-009-0594-5.PubMedCrossRef

136.

De Sousa, A. (2010). The pharmacotherapy of alcohol dependence: a state of the art review. Mens Sana Monographs, 8(1), 69–82. https://doi.org/10.4103/0973-1229.58820.PubMedPubMedCentralCrossRef

137.

Chen, D., Cui, Q. C., Yang, H., & Dou, Q. P. (2006). Disulfiram, a clinically used anti-alcoholism drug and copper-binding agent, induces apoptotic cell death in breast cancer cultures and xenografts via inhibition of the proteasome activity. Cancer Research, 66(21), 10425–10433. https://doi.org/10.1158/0008-5472.can-06-2126.PubMedCrossRef

138.

Pang, H., Chen, D., Cui, Q. C., & Dou, Q. P. (2007). Sodium diethyldithiocarbamate, an AIDS progression inhibitor and a copper-binding compound, has proteasome-inhibitory and apoptosis-inducing activities in cancer cells. International Journal of Molecular Medicine, 19(5), 809–816.PubMed

139.

Milacic, V., Chen, D., Giovagnini, L., Diez, A., Fregona, D., & Dou, Q. P. (2008). Pyrrolidine dithiocarbamate-zinc(II) and -copper(II) complexes induce apoptosis in tumor cells by inhibiting the proteasomal activity. Toxicology and Applied Pharmacology, 231(1), 24–33. https://doi.org/10.1016/j.taap.2008.03.009.PubMedPubMedCentralCrossRef

140.

Cvek, B., Milacic, V., Taraba, J., & Dou, Q. P. (2008). Ni(II), Cu(II), and Zn(II) diethyldithiocarbamate complexes show various activities against the proteasome in breast cancer cells. Journal of Medicinal Chemistry, 51(20), 6256–6258. https://doi.org/10.1021/jm8007807.PubMedPubMedCentralCrossRef

141.

Nardon, C., Chiara, F., Brustolin, L., Gambalunga, A., Ciscato, F., Rasola, A., et al. (2015). Gold(III)–pyrrolidinedithiocarbamato derivatives as antineoplastic agents. ChemistryOpen, 4(2), 183–191. https://doi.org/10.1002/open.201402091.PubMedPubMedCentralCrossRef

142.

Liu, N., Liu, C., Li, X., Liao, S., Song, W., Yang, C., et al. (2014). A novel proteasome inhibitor suppresses tumor growth via targeting both 19S proteasome deubiquitinases and 20S proteolytic peptidases. Scientific Reports, 4, 5240. https://doi.org/10.1038/srep05240.PubMedPubMedCentralCrossRef

143.

Zhao, C., Chen, X., Zang, D., Lan, X., Liao, S., Yang, C., et al. (2016). A novel nickel complex works as a proteasomal deubiquitinase inhibitor for cancer therapy. Oncogene, 35(45), 5916–5927. https://doi.org/10.1038/onc.2016.114.PubMedPubMedCentralCrossRef

144.

Zhao, C., Chen, X., Yang, C., Zang, D., Lan, X., Liao, S., et al. (2017). Repurposing an antidandruff agent to treating cancer: zinc pyrithione inhibits tumor growth via targeting proteasome-associated deubiquitinases. Oncotarget, 8(8), 13942–13956. 10.18632/oncotarget.14572.PubMedPubMedCentral

145.

Zhao, C., Chen, X., Zang, D., Lan, X., Liao, S., Yang, C., et al. (2016). Platinum-containing compound platinum pyrithione is stronger and safer than cisplatin in cancer therapy. Biochemical Pharmacology, 116, 22–38. https://doi.org/10.1016/j.bcp.2016.06.019.PubMedPubMedCentralCrossRef

146.

Tomasello, M. F., Nardon, C., Lanza, V., Di Natale, G., Pettenuzzo, N., Salmaso, S., et al. (2017). New comprehensive studies of a gold(III) dithiocarbamate complex with proven anticancer properties: aqueous dissolution with cyclodextrins, pharmacokinetics and upstream inhibition of the ubiquitin-proteasome pathway. European Journal of Medicinal Chemistry, 138, 115–127. https://doi.org/10.1016/j.ejmech.2017.06.013.PubMedCrossRef

147.

An, H., & Statsyuk, A. V. (2015). An inhibitor of ubiquitin conjugation and aggresome formation. Chemical Science, 6(9), 5235–5245. https://doi.org/10.1039/c5sc01351h.PubMedPubMedCentralCrossRef

148.

Yang, Y., Kitagaki, J., Dai, R. M., Tsai, Y. C., Lorick, K. L., Ludwig, R. L., et al. (2007). Inhibitors of ubiquitin-activating enzyme (E1), a new class of potential cancer therapeutics. Cancer Research, 67(19), 9472–9481. https://doi.org/10.1158/0008-5472.can-07-0568.PubMedCrossRef

149.

Xu, G. W., Ali, M., Wood, T. E., Wong, D., Maclean, N., Wang, X., et al. (2010). The ubiquitin-activating enzyme E1 as a therapeutic target for the treatment of leukemia and multiple myeloma. Blood, 115(11), 2251–2259. https://doi.org/10.1182/blood-2009-07-231191.PubMedPubMedCentralCrossRef

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Targeting the ubiquitin-proteasome system for cancer treatment: discovering novel inhibitors from nature and drug repurposing

Abstract

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2017

The ubiquitin-proteasome pathway in adult and pediatric brain tumors: biological insights and therapeutic opportunities

Biography—Q. Ping Dou

(Immuno)proteasomes as therapeutic target in acute leukemia

Emerging small molecule approaches to enhance the antimyeloma benefit of proteasome inhibitors

Proteasome dysregulation in human cancer: implications for clinical therapies

Ubiquitin carboxyl-terminal hydrolases: involvement in cancer progression and clinical implications

Keynote webinar | Spotlight on antibody–drug conjugates in cancer